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Objective. Lyme arthritis (LA) is caused by infection with Borrelia burgdorferi and usually resolves following spirochetal killing with antibiotics. However, in some patients, arthritis persists after antibiotic therapy. To provide insights into underlying pathogenic processes associated with antibiotic-refractory LA (postinfectious LA), we analyzed differences in microRNA (miRNA) expression between LA patients with active infection and those with postinfectious LA.
Methods. MicroRNA expression was assayed in synovial fluid (SF) from LA patients before and after oral and intravenous antibiotic therapy, and in synovial tissue obtained months after antibiotic therapy from patients with postinfectious LA. SF and tissue from patients with other forms of arthritis, such as rheumatoid arthritis (RA) and osteoarthritis, were used for comparison.
Results. SF from LA patients during active infection had marked elevations of white blood cells, particularly polymorphonuclear leukocytes, accompanied by elevated levels of microRNA-223 (miR-223). In contrast, SF from postantibiotic LA patients contained greater percentages of lymphocytes and mononuclear cells. SF from postantibiotic LA patients also exhibited marked inflammatory (miR-146a, miR-155), wound repair (miR-142), and proliferative (miR-17-92) miRNA signatures, and higher levels of these miRNAs correlated with longer arthritis duration. Levels of miR-146a, miR-155, miR-142, miR-223, and miR-17-92 were also elevated in synovial tissue in late postinfectious LA, and levels of let-7a were reduced, similar to RA.
Conclusion. During active infection, miRNA expression in SF reflected an immune response associated with bacterial killing, while in postinfectious LA, miRNA expression in SF and synovial tissue reflected chronic inflammation, synovial proliferation, and breakdown of wound repair processes, showing that the nature of the arthritis was altered after spirochetal killing.
Bacterial infection normally elicits robust and effective immune responses. However, failure to resolve immune responses following pathogen clearance can result in tissue damage. These responses are tightly regulated by microRNAs (miRNAs), which are needed to enhance or limit a large number of biologic processes, including immune responses to infection (1) .
MicroRNAs are small noncoding RNAs that bind the 3 0 -untranslated region of target messenger RNAs (mRNAs) and inhibit translation, thereby acting as finetuners of gene expression (2) . MicroRNAs provide robustness to gene regulation (3) , and defects in miRNAs can contribute to a number of pathologies, including inflammatory and autoimmune diseases (1) . For example, a recent miRNA study showed that rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease, had the most significant enrichment of miRNA-target gene risk factors of any disease studied (4) . Moreover, mouse studies have shown that microRNA-155 (miR-155) (5), miR-223 (6) , and miR-146a (7) directly modulate experimental models of arthritis, consistent with the role of miRNAs and other epigenetic regulatory factors in the pathogenesis of RA in humans (8) .
Using mouse models of Lyme disease, we have shown that miR-146a and miR-155 are up-regulated during infection with the Lyme disease spirochete Borrelia burgdorferi and that they act as negative (miR-146a) and positive (miR-155) regulators of immune activation (9, 10) . These 2 miRNAs help to fine-tune the immune response, ensuring effective spirochetal killing while limiting tissue damage. Mice lacking either miR-146a or miR-155 have more severe Lyme arthritis (LA) or carditis, respectively, suggesting important roles for these miRNAs in balancing immune activation and tissue damage (9, 10) .
Other miRNAs associated with immune regulation and cell proliferation also show altered expression in joints of infected mice that developed severe LA (9) . These include miR-142, associated with immune modulation (11, 12) and tissue remodeling (13, 14) ; miR-17-92 cluster, associated with cell proliferation and oncogenesis (15) (16) (17) ; and let-7 family members, associated with tumor suppression (18) . However, to date, no studies have examined the role of miRNAs in Lyme disease in humans.
LA, the most common late manifestation of Lyme disease, is characterized by intermittent or persistent joint swelling and pain in one or a few large joints, especially the knee (19) . In most patients, the arthritis resolves with spirochetal killing with oral or intravenous (IV) antibiotic therapy. However, in some patients, synovitis persists for months or years after antibiotic therapy. The synovial lesion in these patients shows synovial hypertrophy, vascular proliferation, and mononuclear cell infiltrates, which are also observed in other forms of chronic inflammatory arthritis, including RA (20) . After antibiotic therapy, patients with antibiotic-refractory LA are treated with disease-modifying antirheumatic drugs (DMARDs), the standard treatment used for other inflammatory arthritides (21) .
In this study, we assessed in LA patients the expression of miRNAs that have been previously associated with arthritis pathogenesis (22) . We report that during active infection, miRNA expression reflected an immune response associated with bacterial killing, and joint swelling resolved when that was accomplished. However, following antibiotic therapy and in the absence of active infection, a subset of patients developed a marked proliferative synovitis, previously called antibiotic-refractory LA but hereafter termed postinfectious LA. In these patients, miRNA expression profiles reflected inflammatory and proliferative dysregulation involved in pathogenesis of postinfectious LA.
PATIENTS AND METHODS
Patients. The present study was approved by the Human Investigations Committee at Massachusetts General Hospital (MGH). All patients with Lyme disease met the Centers for Disease Control and Prevention criteria for B burgdorferi infection (23) , and those with RA, psoriatic arthritis (PsA), undifferentiated inflammatory monoarthritis, or osteoarthritis (OA) met validated criteria for those diseases (24) (25) (26) (27) . LA patients received antibiotic therapy according to an algorithm (28) , as detailed in the guidelines of the Infectious Diseases Society of America (29) .
Sample collection. Patient synovial fluid (SF) was centrifuged at 300g for 10 minutes, then at 3,000g for 10 minutes, and stored at 280˚C. Synovial tissue was collected from arthritis patients who underwent arthroscopic synovectomies. Tissue was placed immediately in RNA stabilization reagent and stored at 220˚C.
RNA purification. RNA was recovered from 200 ml SF using a serum/plasmid miRNeasy kit (Qiagen) or from ;100 mg synovial tissue using an miRNeasy kit. Synovial tissue RNA quality was determined using a Bioanalyzer (Agilent).
SF miRNA expression. MicroRNAs in SF were assayed using miScript Human Serum & Plasma 384HC miRNA polymerase chain reaction (PCR) arrays (MIHS-3106ZG; Qiagen) on an LC-480 light cycler (Roche). Expression levels were normalized to the global geometric mean C t of levels of all expressed miRNAs (C t cutoff 35).
Synovial tissue miRNA expression. Small RNA libraries were generated using the NEBNext multiplex small RNA library prep set for Illumina (New England Biolabs). Quality was determined using a Bioanalyzer. Libraries were sequenced to a depth of ;2,500,000 50-bp reads (MiSeq Reagent Kit version 2; Illumina). Library preparation, sequencing, and bioinformatics were performed by the MGH NextGen Sequencing and Bioinformatics Core Facilities.
Statistical and pathway analysis. A Mann-Whitney U test was used to determine differences in clinical data between groups. Welch's t-test was used to determine differences in miRNA expression between groups. Pearson's correlation coefficients (r) were determined by correlation analysis. Differential expression analysis was used to determine differences in synovial tissue miRNA expression. MicroRNA/mRNA pathway analysis was performed using DIANA miRPath version 2 (30) . Statistical significance (P , 0.05) was determined using GraphPad Prism software version 6.
RESULTS
Patient characteristics. During a 1.5-year period from October 2014 through February 2016, 34 LA patients were enrolled in our study, 18 of whom had evaluable SF samples available. Additionally, from 2004 to 2015, 14 LA patients underwent arthroscopic synovectomy, and evaluable synovial tissue from these patients was available. Thus, for this study, we evaluated 32 LA patients from whom we could obtain extracellular miRNA from SF or miRNA from synovial tissue. These patients were representative of the spectrum of disease severity and treatment responses seen in this disease (31) . Because inflammation in LA is localized to affected joints, we present data only for patients from whom SF or synovial tissue was available.
Of the 18 patients from whom SF was collected, 5 were referred prior to antibiotic therapy when they had active B burgdorferi infection (group 1, preantibiotic patients) ( Table 1) . The other 13 patients from whom SF was available were referred because of incomplete responses to oral doxycycline or IV ceftriaxone (group 2, postantibiotic patients). SF was usually collected from these patients soon after oral or IV therapy, when few if any spirochetes remained (32) , and prior to starting DMARD therapy, usually methotrexate (MTX). In patients from whom multiple samples were available, the first sample collected was analyzed. MicroRNA from synovial tissue, a target tissue of this disease, was available from 14 patients who underwent arthroscopic synovectomies between 4 and 48 months (median 15.5 months) after oral and IV antibiotics (group 3, synovectomy patients). In these patients, DMARDs were stopped several weeks prior to synovectomy. Group 1. The 5 patients who were referred prior to antibiotic therapy had mild-to-severe knee swelling and pain for a median duration of 1 month prior to evaluation and the start of antibiotic treatment ( Table 1) . As was typical in our previous cohorts, titers of antibodies to B burgdorferi were high prior to therapy (33) , and PCR results for B burgdorferi DNA in SF were positive for 2 of the 4 patients tested (50%) (32) . In addition, consistent with past experience (19, 31) , the median white blood cell (WBC) count in SF was 25,760 cells/mm 3 with 90% polymorphonuclear leukocytes (PMNs). Arthritis in 3 of the 5 patients resolved during a 1-month course of oral doxycycline, while the other 2 patients continued to have marked knee swelling. These 2 patients were then treated for 1 month with IV ceftriaxone, and their arthritis resolved.
As determined by quantitative reverse transcription-PCR, the 5 patients with active infection who were seen prior to antibiotic therapy had low levels of 5 of the 6 miRNAs measured in this study, including hematopoieticspecific miR-146a, miR-155, and miR-142 (14, 34) , which are associated with myeloid cell effector function ( Figure 1 ). Levels of miR-17 and miR-20a, part of the miR-17-92 oncomiR family involved in cell cycle regulation (15) , were also low. The notable exception was high levels of miR-223, a hematopoietic-specific miRNA that is abundantly expressed in PMNs (34) . MicroRNA-223 is associated with down-regulation of acute inflammation (35) and tissue (36) . This finding is consistent with high levels of PMNs present in SF from these patients. Group 2. The 13 patients who continued to have joint swelling after oral or IV antibiotic therapy exhibited marked variability in the severity and duration of their arthritis, which is consistent with heterogeneity of treatment outcomes in LA in humans. These patients were referred because of incomplete responses to oral or IV antibiotic therapy between 2.75 and 17 months after arthritis onset (Table 1) . Of the 13 patient samples, 7 were collected after completion of oral antibiotic therapy but before IV antibiotic therapy, and 6 were collected after completion of both oral and IV antibiotic therapy but before DMARD therapy. Compared with patients in group 1, who were seen prior to antibiotic therapy, those in group 2 had significantly lower WBC counts in SF (P 5 0.008), fewer PMNs (P 5 0.004), and greater percentages of lymphocytes (P 5 0.008) and monocytes (P 5 0.028). Arthritis in 2 of these 13 patients resolved after IV antibiotic therapy; most of the other 11 patients were treated successfully with MTX, and none had reactivation of infection during or after immunosuppressive therapy.
In contrast to the low levels of most miRNAs found in group 1, levels of miR-146a, miR-155, miR-142, miR-17, and miR-20a were higher in group 2 (Figure 1) . This suggested that the nature of the arthritis had changed after spirochetal killing. The exception was miR-223, which was typically elevated in patients in both group 1 and group 2. However, of the 5 patients in group 1, the 2 patients who required IV antibiotic therapy for resolution of arthritis had higher levels of miR-142 and miR-223 (open circles in Figure 1 ) than did the 3 patients whose arthritis was resolved with oral therapy (solid circles in Figure 1 ). Conversely, of the 13 patients who were seen in the postantibiotic period, the 2 patients whose arthritis resolved with IV therapy (open squares in Figure 1 ) had low-to-moderate levels of miR-155 and miR-142.
For comparison, miRNAs were also assessed in SF from 4 patients with OA, a minimally inflammatory type of arthritis, and in SF from 6 patients with RA, the prototypic form of chronic inflammatory arthritis. Levels of all 6 miRNAs in RA patients were similar to those in LA patients in group 2, while levels of most of these miRNAs in OA patients were low and similar to those in LA patients in group 1 (Figure 1) . Levels of miR-223 were high in all LA patients; they were particularly high in RA patients but very low in OA patients. When the cell composition of SF from patients in group 1 was considered together with that of SF from patients in group 2, changes in cellularity correlated with arthritis duration prior to sample collection ( Figure  2B ). Arthritis duration correlated negatively with the WBC count (P 5 0.022) and the percentage of PMNs (P 5 0.002) and positively with the percentages of lymphocytes (P 5 0.044) and mononuclear cells (P 5 0.011). These results further suggested that the pathologic characteristics of the arthritis changed during transition from active infection to postinfectious LA and that these miRNAs may have a role in arthritis pathogenesis.
Group 3. RNA from synovial tissue was available from 14 patients who underwent synovectomies for treatment of persistent synovitis a median of 15.5 months (range 4-48 months) after 2-3 months of antibiotic therapy (Table 1) . Two patients (14%) required a second synovectomy; both of these patients declined DMARD therapy prior to their first synovectomy, while the other 12 patients did not. All 14 patients had negative culture and PCR results for B burgdorferi and B burgdorferi DNA (32) . SF from these patients was not available for testing.
To assess miRNA expression in synovial tissue, the 14 samples from LA patients were analyzed using miRNA sequencing, allowing a global assessment of all miRNAs. MicroRNA sequencing was not possible with the smaller amounts of RNA in cell-free SF. For comparison, we assessed synovial tissue from 8 patients with other forms of inflammatory arthritis (5 with RA, 2 with PsA, and 1 with undifferentiated inflammatory monoarthritis) and from 5 patients with minimally inflammatory OA. A total of 73 miRNAs were differentially expressed in synovial tissue from patients with postinfectious LA compared with that from OA patients. A complete list of miRNAs differentially expressed in each patient group is provided in Supplementary These 73 differentially expressed miRNAs were subjected to further analysis to determine which genes and pathways were predicted to be regulated by them Table 2) . Genes predicted to be regulated by 44 miRNAs overexpressed in synovial tissue from LA patients were involved in cellular proliferation or regulation of inflammatory processes, such as T cell receptor signaling, B cell receptor signaling, and antibodymediated phagocytosis. In contrast, the 29 miRNAs overexpressed in synovial tissue from OA patients were predicted to be involved in tissue remodeling and cell proliferation but not inflammation, consistent with the nature of OA. Thus, miRNAs in synovial tissue from patients with postinfectious LA predominantly regulated 2 processes, inflammation and proliferation, while miRNAs in this tissue in OA primarily regulated proliferation.
As with all forms of chronic inflammatory arthritis, synovial lesions in the 14 patients with postinfectious LA were characterized by massive, tumor-like proliferation of inflamed synovial tissue that can invade cartilage and bone (Figure 3) . MicroRNA sequencing analysis of inflamed synovial tissue showed high expression of many miRNAs that were also abundant in SF from postantibiotic LA patients in group 2. These included antiinflammatory miR-146a and proinflammatory miR-155 ( Figure 3A) , which are associated with Toll-like receptor (TLR)/NF-kB inflammation (37) , as well as hematopoietic-specific miRNAs such as miR-142 and miR-223 ( Figure 3B ), which are associated with myeloid function, modulation of acute inflammation, and initiation of wound repair (11, 12, 14, 36) . While expression levels of most miRNAs were similar between male and female patients, levels of miR-146a were 2.9-fold higher in males and 1.4-fold higher in females in synovial tissue from patients with postinfectious LA compared with that from OA patients.
As in SF, synovial tissue miRNA expression also contained a distinct oncogenic miRNA profile and was similar between male and female patients. Levels of the oncomiRs miR-17 and miR-20a were approximately 2.5-fold to 4-fold higher in synovial tissue from patients with postinfectious LA compared with that from OA patients ( Figure 3C) ; levels of let-7a and let-7c, which are tumor suppressor miRNAs (18) , were approximately 2-fold lower ( Figure 3D ). Thus, in these patients, the transition to the postinfectious phase was blocked by chronic inflammation, which stalled the wound repair process. Both inflammatory and proliferative miRNA responses were altered in these patients, indicative of development of an inflamed, tumor-like synovial lesion, analogous to a chronic synovial wound.
Correlation of miRNA signature in synovial tissue with disease duration. In contrast to findings in SF (Figure 2) , expression of the NF-kB-inducible miRNAs miR-146a and miR-155 did not correlate significantly with arthritis duration after the start of antibiotic therapy (Figure 4) . However, expression of miR-223 and the oncomiR miR-17-92 cluster in tissue correlated positively with arthritis duration after the start of treatment, while the let-7 family of tumor suppressor miRNAs correlated negatively with posttreatment arthritis duration (Figure 4) . Each of these correlations was similar when analyzed with the estimated total arthritis duration (data not shown). Thus, in synovial tissue obtained late in disease, miRNAs involved in proliferative responses correlated with arthritis duration, but chronically elevated inflammatory miRNAs did not.
These synovial tissue results showed that late in postinfectious LA, TLR/NF-kB-dependent miRNAs were constitutively expressed, and the tumor-associated miRNA signature became progressively more pronounced. This suggested that expression of these miRNAs reflected immune dysregulation in the synovial tissue of patients with postinfectious LA, possibly perpetuating chronic inflammation and synovial proliferation in these patients. 
DISCUSSION
In this study, patients who were seen prior to antibiotic therapy had a high number of infiltrating leukocytes in SF, primarily PMNs (Table 1) , and elevated levels of miR-223, which is highly expressed in PMNs (36) . In contrast, they had very low levels of other hematopoietic-specific miRNAs, such as miR-146a, miR-155, and miR-142, similar to levels in SF in patients with OA (Figure 1 ). Low levels of these miRNAs, especially miR-146a and miR-155, suggested that inflammatory processes such as TLR/NF-kB signaling were tightly regulated in the joints of these patients despite the presence of spirochete-derived TLR ligands. Thus, during active infection, immune responses were focused on bacterial killing, primarily through controlled inflammation, antibody production, and PMN infiltration in SF of infected joints. After antibiotic therapy, arthritis in most patients was resolved by down-regulation of antibacterial responses, allowing for appropriate transition to wound repair and arthritis resolution.
We were unable to obtain SF or synovial tissue from these LA patients in the postinfectious phase, since their arthritis resolved during antibiotic therapy. However, we speculate that in such patients, the transition from infectious LA to the postinfectious phase occurs rapidly, progressing to beneficial wound repair responses after spirochetes have been killed. As a result, we would expect miRNA expression profiles after antibiotic therapy to look similar to those observed in synovial tissue from OA patients, characterized by tissue repair with minimal inflammation.
Animal models of LA provide insights into these processes in LA in humans. When infected with B burgdorferi, C57BL/6 mice develop only mildly-to-moderately inflammatory LA (38) . They rely on antibody responses to B burgdorferi to control the infection, accompanied by robust wound repair responses. In contrast, B burgdorferi-infected C3H/HeN mice develop severe arthritis, have a massive cellular immune response dominated by interferon-a/b (IFNa/b)/STAT-1 activation in joint tissue early in infection, and have down- regulated wound repair responses (39) . However, unlike postinfectious LA in humans, neither mouse strain has persistent arthritis after antibiotic therapy.
Despite these differences, joints of C3H/HeN and C57BL/6 mice have similar numbers of spirochetes, indicating that the cellular response in C3H/HeN mice is maladaptive, worsening tissue damage without enhancing host defense (38) . We suspect that in humans, genetic variables determine whether B burgdorferi infection elicits an appropriate wound repair response (as in C57BL/6 mice) (40, 41) or a maladaptive inflammatory cellular response and arrest of wound repair processes (as in C3H/HeN mice) (42) . For example, patients who have a polymorphism in the TLR-1 gene (1805GG), found primarily in the European Caucasian population, have higher levels of IFNg/STAT-1-dependent cytokines when infected with RST1 B burgdorferi strains, and they have an increased frequency of postinfectious LA (43) .
While arthritis was resolved in all of the preantibiotic LA patients from group 1 after completion of 1-3 months of antibiotic therapy, the LA patients from groups 2 and 3 were tested in the postantibiotic phase, when few if any spirochetes remained in affected joints. Compared with patients in group 1, patients in group 2 had longer arthritis duration, fewer WBCs and PMNs in SF, and greater frequencies of lymphocytes and monocytes (Table 1 and Figure 2B ). A number of miRNAs associated with NF-kB inflammation (miR-146a, miR-155), myeloid cell function and wound repair (miR-142, miR-223), and Myc-dependent cell cycle regulation (miR-17-92, let-7 family) were highly expressed in SF and synovial tissue in patients from groups 2 and 3 (Figures 1 and  3) . These results suggest that the inflammatory and proliferative processes occurring in the synovial environment in postinfectious LA were indeed maladaptive and were consistent with tumor-like characteristics of the synovial lesion, as has been described in RA (44) .
The chronically high levels of miR-155 in SF and synovial tissue of patients with postinfectious LA provided valuable insights into the nature of their dysregulated inflammation. In mice, miR-155 is strongly up-regulated upon TLR/NF-kB activation but rapidly down-regulated in the presence of interleukin-10 (IL-10) in a STAT-3-dependent manner (45) . When infected with B burgdorferi, IL-10 2/2 mice, which lack this IL-10/STAT-3/miR-155 regulatory mechanism, have very high miR-155 levels as well as a strong IFNg/STAT-1 cytokine profile, enhancing cellular and humoral responses to infection (10) . In contrast, infected C3H/HeN and C57BL/6 mice retain this IL-10/ STAT-3/miR-155 regulatory loop and have low miR-155 miRNAs IN POSTINFECTIOUS LYME ARTHRITISlevels in joint tissue, despite differences between strains in LA severity (9) .
While IL-10 2/2 mice had down-regulated IFNg/ STAT-1 responses in joints after spirochetes had been killed with antibiotics (46), some LA patients have persistent inflammation months or years following completion of antibiotic therapy. We speculate that in postinfectious LA, elevated miR-155 indicates constitutive activation of proinflammatory pathways resulting from elevated cytokines such as IL-1b or tumor necrosis factor, from retained pathogen-associated molecular patterns (47) , or from host damage-associated molecular patterns. Mice that chronically overexpress miR-155 spontaneously develop autoimmune T and B cell responses (48) . Similarly, chronic overexpression of miR-155 in patients might also be a factor contributing to autoimmunity in LA (49) (50) (51) (52) (53) and RA (22) in humans.
In the present study, miRNA expression in patients with postinfectious LA was most similar to expression in RA patients. Consistent with these results, elevated expression of miR-155, miR-146a, and miR-223 has previously been shown in SF, synovial tissue, and synovial fibroblasts from patients with RA (22) . Furthermore, studies in mice have demonstrated that miR-155 and miR-223 contribute to more severe experimental arthritis (5, 6) , and miR-146a limits inflammation and tissue damage in experimental arthritis (7, 46) . However, while the initial inflammatory triggers in RA are not clear, the initial trigger of LA, infection with B burgdorferi, is known with certainty. This makes it possible to study immune responses at their inception, when the stage is being set for subsequent arthritis. Moreover, the comparison of patients with antibiotic-responsive LA and those with postinfectious LA provides a unique opportunity to implicate genetic and regulatory factors that lead to this disadvantageous outcome.
Our study population, which is based on referrals, was representative of the range of possible outcomes in LA. It is unusual that patients are referred prior to therapy with oral doxycycline, and none of the patients referred prior to therapy developed postinfectious LA, which occurs in fewer than 10% of patients with LA (19) . Instead, patients are usually referred because of lack of response to oral or IV antibiotic therapy. Therefore, our patient cohort is representative of the severe end of the spectrum of patients who do not respond well to antibiotic therapy. Moreover, SF cannot be obtained from all patients, and synovial tissue, the target tissue of the disease, is nearly always collected late in the postinfectious course in those who undergo arthroscopic synovectomies. Nevertheless, this study provides a novel assessment of miRNA expression in affected joints of patients during the infectious and postinfectious phases of LA.
Finally, the noted similarities in miRNA expression between postinfectious LA and other forms of chronic inflammatory arthritis, including RA, support the practice of treating patients with postinfectious LA with DMARDs after appropriate antibiotic therapy (21) . Currently, these patients are usually treated with 2-3 months of oral and IV antibiotic therapy followed by ;6-9 months of DMARD therapy, usually with MTX (21) . With this regimen, we have not observed relapse of infection during the period of immunosuppressive DMARD therapy. However, this treatment algorithm requires a total of $1 year of therapy, sometimes followed by months of physical therapy to regain normal function. MicroRNAs hold promise as potential biomarkers to identify LA patients who are developing maladaptive immune responses during the period of infection. In such patients, it will be important to learn whether simultaneous treatment with antibiotics and DMARDs, rather than sequential treatment with these medications, will reduce the period of therapy and improve outcome, creating a new paradigm in treatment of this form of chronic inflammatory arthritis.
